Continuous flow chamber device for separation, concentration, and/or purification of cells

• US 20060183223A1
• Filed: 01/20/2006
• Published: 08/17/2006
• Est. Priority Date: 01/21/2005
• Status: Abandoned Application

• Current Assignee: University of Rochester
• Original Assignee: University of Rochester
• Inventors: Gentile, John P., Charles, Nichola, Mody, Nipa A., Liesveld, Jane, Clark, Nathan, King, Michael R.
• Application Number:
  US11/335,573
• Publication Number:
  US 20060183223A1
• Time in Patent Office: Days
• US Class Current: 435/372
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.

Claims

1. A method for separating, concentrating, and/or purifying a particular cell type from a mixture of cells comprising the steps of

providing a flow surface containing an adhesive molecule that selectively binds with the particular cell type;

and

flowing the mixture of cells on the flow surface.

2. The method of claim 1, wherein the particular type of cell is selected from the group consisting of CD34+ cell and hematopoietic stem and precursor cell (HSPC).

3. The method of claim 1, wherein the substance is selected from the group consisting of NPPB, P-selectin, L-selectin, E-selectin, antibody specific against the particular cell type, cadherins, integrins, mucin-like family, immunoglobin superfamily and fragments thereof.

4. The method of claim 1, wherein the flow surface is part of a separation chamber.

5. The method of claim 1, wherein the flow surface is part of a microcapillary network.

6. The method of claim 1, wherein the wall shear stress is about 1-10 dyn/cm².

7. The method of claim 1, wherein the particular cell type has a rolling speed less than half the rolling speed of the other cells in the mixture of cells.

8. An implantable shunt for directing stem cell trafficking comprising a flow chamber, wherein a wall of the chamber contains an adhesive molecule that selectively binds with the stem cell.

9. The implantable shunt of claim 8, wherein the stem cell is CD34+ hematopoetic stem cell.

10. The implantable shunt of claim 8, wherein the molecule is selected from the group consisting of NPPB, P-selectin, L-selectin, E-selectin, antibody specific against the particular cell type, cadherins, integrins, mucin-like family, immunoglobin superfamily and fragments thereof.

11. An implantable device for neutralizing tumor cells comprising a flow chamber, wherein a wall of the chamber contains an adhesive molecule that selectively binds with the tumor cells and a molecule that neutralizes the cancer cells.

12. The implantable device of claim 11, wherein the adhesive molecule is selectin.

13. The implantable device of claim 11, wherein the molecule that neutralizes the cancer cells is selected from the group consisting of TRAIL, Fas ligand, and chemotherapeutic drug.

14. The implantable device of claim 11, wherein the molecule that neutralizes the cancer cells induces apoptosis in the tumor cells.

15. A method for neutralizing tumor cells comprising the steps of

providing a flow surface containing an adhesive molecule that selectively binds with the tumor cells and a molecule that neutralizes the cancer cells;

and

flowing the tumor cells on the flow surface.

16. The method of claim 15, wherein the adhesive molecule is selected from the group consisting of NPPB, P-selectin, L-selectin, E-selectin, antibody specific against the particular cell type, cadherins, integrins, mucin-like family, immunoglobin superfamily and fragments thereof.

17. The method of claim 15, wherein the molecule that neutralizes the cancer cells is selected from the group consisting of TRAIL, Fas ligand, and chemotherapeutic drug.

18. The method of claim 15, wherein the molecule that neutralizes the cancer cells induces apoptosis in the tumor cells.

19. The method of claim 15, wherein the flow surface is part of a separation chamber.

20. The method of claim 15, wherein the flow surface is implanted in the circulatory system of a patient.